Obeticholic Acid Market Report 2026

The obeticholic acid market size has grown rapidly in recent years. It will grow from $1.01 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to clinical approval for primary biliary cholangitis treatment, rising liver disease diagnosis, expansion of hepatology clinics, increased awareness of bile acid regulation therapies, growth in specialty liver drugs.

The obeticholic acid market size is expected to see rapid growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing NASH patient population, expansion of liver disease drug pipelines, improved diagnostic screening adoption, rising investment in hepatology research, global expansion of oral liver therapies. Major trends in the forecast period include rising prevalence of chronic liver diseases, increasing adoption of FXR agonist therapies, growing focus on disease-modifying liver drugs, expansion of nonalcoholic steatohepatitis research, increasing use of oral hepatology treatments.

The increasing incidence of liver diseases is expected to drive the demand for obeticholic acid in the coming years. Liver diseases are disorders that impair the liver's normal functioning. This rise in liver diseases is primarily attributed to excessive alcohol consumption, which can cause liver inflammation, cirrhosis, and liver failure by damaging liver cells and reducing the organ's ability to operate effectively. Obeticholic acid aids patients with liver diseases by activating the farnesoid X receptor (FXR), which lowers bile acid accumulation, diminishes liver inflammation, and slows the progression of fibrosis, ultimately enhancing liver function. For example, in December 2024, the Office for Health Improvement and Disparities, a UK government department, reported that premature deaths from alcoholic liver disease rose by 3.6% in 2023, reaching 5,984, up from 5,776 in 2022. Consequently, the growing prevalence of liver diseases is contributing to the expansion of the obeticholic acid market.

Major companies operating in the obeticholic acid sector are focusing on developing innovative therapies, such as farnesoid X receptor (FXR) agonists, to enhance liver disease management and improve patient outcomes. A farnesoid X receptor (FXR) agonist is a compound that stimulates the FXR, a nuclear receptor that plays a key role in regulating bile acid metabolism, inflammation, and fibrosis in the liver. Farnesoid X receptor (FXR) agonists aid in improving liver function and are utilized in treating conditions like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For example, in February 2024, Intercept Pharmaceuticals Inc., a US-based biopharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva to treat patients with primary biliary cholangitis (PBC). The FDA's acceptance of the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) represents a regulatory milestone toward confirming its clinical benefits in managing PBC.

In November 2023, Alfasigma, a pharmaceutical company based in Italy, acquired Intercept Pharmaceuticals, Inc. for USD 19.0 per share in cash. Through this acquisition, Alfasigma seeks to enhance its presence in the U.S. and broaden its portfolio in gastroenterology and hepatology. Intercept Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company dedicated to developing therapies for rare and serious liver diseases, including primary biliary cholangitis (PBC), with its leading product being Ocaliva.

Major companies operating in the obeticholic acid market are Intercept Pharmaceuticals Inc., Genfit, Gilead Sciences Inc., Pfizer Inc., Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Alembic Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Cadila, Teva Pharmaceutical Industries Ltd., WuXi AppTec, Viva Life Sciences, Omgene Life Sciences Pvt. Ltd., Enanta Pharmaceuticals, Novo Nordisk A/S, AstraZeneca plc, Roche Holding AG, Sanofi S.A.

North America was the largest region in the Obeticholic Acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the obeticholic acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the obeticholic acid market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and excipients used in bile acid-based therapies. These impacts have been most pronounced in specialty liver drug segments, particularly in north america and europe. Asia-pacific manufacturers have faced procurement delays and cost pressures. However, tariffs have supported localized API production and formulation, improving supply continuity.

The obeticholic acid market research report is one of a series of new reports that provides obeticholic acid market statistics, including obeticholic acid industry global market size, regional shares, competitors with a obeticholic acid market share, detailed obeticholic acid market segments, market trends and opportunities, and any further data you may need to thrive in the obeticholic acid industry. This obeticholic acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Obeticholic acid is a drug mainly prescribed for managing liver conditions, particularly in patients with primary biliary cholangitis (PBC), a long-term liver disorder. It is a synthetic bile acid that functions by stimulating a receptor known as the farnesoid X receptor (FXR), which aids in controlling bile acid synthesis, supporting liver function, and reducing inflammation.

The primary product forms of obeticholic acid include tablets, capsules, and other variants. Tablets are solid dosage forms intended for easy oral administration. The drug is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used to manage nonalcoholic steatohepatitis, primary biliary cholangitis, and other related conditions.

The obeticholic acid market consists of sales of products including tablets, generic obeticholic acid, ocaliva support services, patient education kits, and obeticholic acid + ursodeoxycholic acid (UDCA). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.